A personalized “cancer vaccine" may help keep a deadly form of skin cancer from growing for years, a small new study in humans suggests.
Publications
Melanoma Vaccine from NeoVox Shows Anti-Tumor Response Four Years Later
In encouraging news regarding melanoma therapy, researchers found that a personalized vaccine continues to keep cancer cells in check four years after patients received it.
Eganelisib/Nivolumab Combo Shows Positive Responses in Head and Neck Carcinoma, Melanoma
Positive response and disease control rates were observed in 2 separate studies when patients with head and neck squamous cell carcinoma (HNSCC) and melanoma received the combination of eganelisib (IPI-549), a selective PI3K-? inhibitor, and nivolumab (Opdivo).
Deciding Between Adjuvant Targeted Therapy and Immunotherapy in BRAF+ Melanoma
When selecting between an adjuvant targeted therapy or immunotherapy for a patient with melanoma, it’s important to consider several factors, including the biologic behavior of the tumor, any comorbidities, toxicities, and patient concerns, according to Reinhard Dummer, MD.